MM&M12h
Rx Rundown: Roche, Metsera, Intercept Pharmaceuticals and more
AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...
poandpo.com15h
BioNTech buys China’s Biotheus in $800 million push into cancer drugs
BioNTech SE and Biotheus announced the signing of a definitive agreement for the acquisition of Biotheus, a clinical-stage ...
The Chemical Engineer16h
BioNTech to acquire Chinese oncology startup for almost US$1bn
RESEARCHERS from SINTEF have developed a “simpler” low-cost carbon capture and storage (CCS) system for sequestering ...
Pharmabiz17h
BioNTech to acquire clinical-stage biotech company, Biotheus to boost oncology strategy
BioNTech to acquire clinical-stage biotech company, Biotheus to boost oncology strategy: Mainz, Germany Friday, November 15, 2024, 14:00 Hrs [IST] BioNTech SE and Biotheus (Biothe ...
Instil Bio price target lowered to $110 from $120 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Instil Bio (TIL) to $110 from $120 and keeps a Buy rating on the shares post the Q3 ...